|
THE FEMALE HEALTH COMPANY REPORTS: MEDIA ALERT: THE FEMALE CONDOM PROVIDES COST-EFFECTIVE HIV PREVENTION, ACCORDING TO NEWLY RELEASED STUDIES Research results to be presented Wednesday, July 19, at National Conference of State Legislatures in Chicago Mary Ann Leeper, Ph.D., president of The Female Health Company, will
present an overview of the work recently discussed at the International
AIDS conference in Durban that showed that including the The Female Condom™
can be a cost-saving tool to stem the increasing spread of sexually
transmitted diseases (STDs) including HIV/AIDS. The presentation will be
at the National Conference of State Legislatures, 10:15 a.m. to noon,
Wednesday, July 19, rooms 313-315, Navy Pier, Chicago. With U.S. Centers
for Disease Control statistics showing increasing HIV infection among
American women, Dr. Leeper will discuss how public health programs and
policies can benefit from including The Female Condom as part of an
integrated public health program to help women protect themselves against
HIV and other sexually transmitted diseases. The Female Condom is the only
woman-controlled method available that will help prevent STDs. ### The Female Health Company, based in Chicago, owns certain worldwide rights to The Female Condom™ including patents that have been issued in the United States, United Kingdom, Japan, France, Italy, Germany, Spain, The People’s Republic of China, Canada, New Zealand, South Korea and Australia. The Female Condom™ is the only available product controlled by a woman that protects against sexually transmitted diseases including HIV/AIDS and unintended pregnancy Safe
Harbor” Statement under the Private Securities Litigation Reform Action
of 1995: The statements in this release which are not historical fact are
forward-looking statements based upon the Company’s current plans and
strategies, and reflect the Company’s current assessment of the risks
and uncertainties related to its business, including such things as
product demand and market acceptance; the economic and business
environment and the impact of governmental regulations, both in the United
States and abroad; the effects of competitive products and pricing
pressures; currency risks; capacity; efficiency and supply constraints;
and other risks detailed in the Company’s press releases, shareholder
communication and Securities and Exchange Commission filings.
Actual events affecting the
Company and the impact of such events on the Company’s operations may
vary from those currently anticipated. For more
information about the Female Health Company, dial toll-free via fax, ### William R. Gargiulo, Jr. Mary Ann Leeper,Ph.D. Yvette Anne Venable 231.526.1244 312.280.1119 312.397.6070 If you have any questions or comments, please send them to us info@femalehealth.com |
|
